|
|
|
| Clinical Efficacy of Pudilan Anti-inflammatory Oral Liquid Combined with Tobramycin Eye Drops in the Treatment of Bacterial Keratitis |
| YANG Fan, WANG Guan, FANG Ying |
| Department of Ophthalmology, Zhengzhou Second People's Hospital, Zhengzhou Henan 450006 |
|
|
|
|
Abstract 【Objective】 To explore the clinical efficacy of Pudilan anti-inflammatory oral liquid combined with Tobramycin eye drops in the treatment of bacterial keratitis. 【Methods】 A total of 82 patients with bacterial keratitis admitted to our hospital from April 2020 to April 2023 were randomly divided into an observation group and a control group, with 41 cases in each group, using a random number table method. The control group was treated with tobramycin eye drops, while the observation group was treated with Pudilan anti-inflammatory oral solution in addition to the control group. Both groups were treated for 14 days. We compared the clinical efficacy, incidence of adverse reactions, clinical symptom scores before and after treatment, levels of interferon γ(IFN-γ), interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α), and immune function indicators between two groups. 【Results】 After treatment, the pain symptom score, secretion symptom score, ulcer area symptom score, and conjunctival congestion symptom score of both groups decreased (P<0.05), and the observation group had a lower score (P<0.05). The total effective rate of the observation group was 92.68%, significantly higher than the control group's 75.61%, and the difference was statistically significant (P<0.05). Compared with before treatment, the serum IFN-γ levels in both groups increased after treatment (P<0.05), and the observation group had a higher level (P<0.05); After treatment, the serum levels of IL-6 and TNF-α decreased in both groups (P<0.05), and the observation group had lower levels (P<0.05). Compared with before treatment, the levels of CD3+ and CD4+ in both groups increased after treatment (P<0.05), and the observation group had a higher level (P<0.05); After treatment, the levels of CD8+ decreased in both groups (P<0.05), and the observation group had a lower level (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 The combination of Pudilan anti-inflammatory oral liquid and Tobramycin eye drops is effective in treating bacterial keratitis, improving clinical symptoms and immune function, reducing inflammatory reactions, and is safe and reliable.
|
|
Received: 28 September 2023
|
|
|
|
|
|
[1] ACHIRON A, ELHADDAD O, REGEV T, et al. PACK cross-linking as adjuvant therapy improves clinical outcomes in culture-confirmed bacterial keratitis[J].Cornea,2022,41(9):1069-1073.
[2] 周文熙,李燕婷,王万杰,等. 泪道探通术联合妥布霉素滴眼液治疗先天性泪囊炎[J].国际眼科杂志,2021,21(1):182-185.
[3] 霍敏,张静,董玉红. 妥布霉素滴眼液治疗重症细菌感染性角膜炎的疗效及炎症因子、T淋巴细胞亚群变化[J].贵州医药,2021,45(9):1409-1410.
[4] 白玉玲,安坤杰,李兴双. 清热解毒、散风除翳法对细菌性角膜炎的作用机制研究[J].世界中医药,2020,15(12):1734-1738.
[5] 刘卫华,戈伟中,丁淑华. 蒲地蓝消炎口服液联合左氧氟沙星眼液治疗细菌性角膜炎42例[J].河南中医,2016,36(10):1811-1813.
[6] 孙旭光. 眼科临床指南解读细菌性角膜炎[M]. 北京:人民卫生出版社,2017:178-180.
[7] 王美华,贾娟,徐丽. 妥布霉素滴眼液和左氧氟沙星滴眼液治疗细菌性结膜炎的疗效观察[J].检验医学与临床,2020,17(3):363-365.
[8] 刘佳敏,曹凯,张子俊,等. 近40年我国细菌性角膜炎病原学及药物敏感性变化Meta分析[J].中华实验眼科杂志,2022,40(2):157-164.
[9] 周生元,范亚莉. 蒲地蓝消炎口服液联合头孢克洛治疗儿童急性化脓性扁桃体炎的疗效观察[J].川北医学院学报,2022,37(9):1139-1142.
[10] 陈果,宋颖辉,王华. 喹诺酮类抗菌药对细菌性角膜炎模型大鼠的干预效果及作用机制[J].中国老年学杂志,2023,43(2):410-413.
[11] 万琪,张志勇,杨硕. 表面活性蛋白在病毒性角膜炎中的作用[J].国际眼科杂志,2021,21(12):2072-2075.
[12] 荣潇,李刚,段建飞,等. 蒲地蓝消炎口服液对小儿手足口病免疫功能及炎性因子的影响[J].中华中医药学刊,2019,37(3):714-717. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 296-298. |
|
|
|
|
2024, Vol. 41 
